posted on 2017-02-14, 00:00authored byYuka E. Lewis, Ana Galesic, Paul M. Levine, Cesar A. De Leon, Natalie Lamiri, Caroline K. Brennan, Matthew R. Pratt
The aggregation of
neurodegenerative-disease associated proteins
can be affected by many factors, including a variety of post-translational
modifications. One such modification, O-GlcNAcylation, has been found
on some of these aggregation prone proteins, including α-synuclein,
the major protein that plays a causative role in synucleinopathies
like Parkinson’s disease. We previously used synthetic protein
chemistry to prepare α-synuclein bearing a homogeneous O-GlcNAc
modification at threonine 72 and showed that this modification inhibits
protein aggregation. However, the effects of the other eight O-GlcNAcylation
sites that have been identified were unknown. Here, we use a similar
synthetic strategy to investigate the consequences of this modification
at one of these sites, serine 87. We show that O-GlcNAcylation at
this site also inhibits α-synuclein aggregation but to a lesser
extent than that for the same modification at threonine 72. However,
we also find that this modification does not affect the membrane-binding
properties of α-synuclein, which differentiates it from phosphorylation
at the same site. These results further support the development of
therapies that can elevate O-GlcNAcylation of α-synuclein to
slow the progression of Parkinson’s disease.